None listed
Conditions
Brief summary
This is a study aiming to evaluate whether metformin, an antidiabetic medication, can be used safety and effectively in patients with type 2 diabetes who are receiving peritoneal dialysis for their end stage kidney disease. The study runs over 4 weeks of active treatment, 250mg of metformin daily orally. We hypothesise that metformin can be safely used in patients with type 2 diabetes with end stage renal failure if dosed based on predicted drug clearance.
Interventions
Metformin 250 mg orally (half a 500mg tablet once a day) for 4 weeks of active treatment while continuing participants' existing peritoneal dialysis treatment. Peritoneal dialysis is not standardised
Sponsors
Tilenka Thynne
Study design
Allocation
Non-randomised trial
Intervention model
Single group
Primary purpose
Treatment
Masking
Open (masking not used)
Eligibility
Sex/Gender
All
Age
18 Years to 100 Years
Healthy volunteers
No
Inclusion criteria
(1)>18 years old (2)Type 2 DM (3)Peritoneal Dialysis treatment of chronic kidney disease (4)Patients in whom metformin would be used if they had normal renal function
Exclusion criteria
(1)Any patient in whom metofrmin would not be used in the setting of normal renal function- moderate-severe heart failure, liver failure, alcohol abuse, major psychaitric disorder, acutely unwell or otherwise medically unstable. (2)Unability or unwilling to measure own blood glucose concentrations via glucometer. (3)Inability to provide written informed consent.
Outcome results
None listed